Guide for patients & caregivers
Positive Scl-70 (Anti-Topoisomerase) Antibody: What Does It Mean?
A positive Scl-70 (anti-topoisomerase) antibody explained: link with systemic sclerosis, why lung screening matters, Raynaud's and rheumatology referral.
Prepared with AI assistance and checked against the cited sources. No independent clinician review has been completed. How we prepare articles
What does a positive Scl-70 antibody mean?
A positive Scl-70 (anti-topoisomerase I) antibody means your blood contains an autoantibody that is strongly associated with systemic sclerosis, also called scleroderma. It is most often found in the diffuse form and is linked with a higher risk of lung scarring. On its own it does not confirm the condition: diagnosis depends on symptoms, examination and other tests.
Scl-70 is usually tested as part of an extractable nuclear antigen (ENA) panel, often after a positive ANA test. Pathology Tests Explained notes it is found in up to about 1 in 5 people with scleroderma, so a negative result does not rule the condition out either.
This guide is for adults reading a positive Scl-70 result. It explains why the result matters and what is commonly checked next; it cannot tell you whether you have systemic sclerosis.
Symptoms that need urgent or earlier care
Call emergency services if you have severe difficulty breathing, your chest feels tight or heavy, pain spreads to your arms, back, neck or jaw, your lips or skin turn very pale, blue or grey, or you become suddenly confused.
Get medical advice sooner, rather than waiting for a routine appointment, if you notice:
- Breathlessness that is new or worse than usual.
- Raynaud's symptoms that are very bad or getting worse, affect only one side of the body, or start for the first time after age 30.
- Raynaud's together with joint pain, skin rashes or muscle weakness.
- Sores or ulcers on the fingertips, swollen puffy fingers, or skin that is thickening or tightening.
Does a positive Scl-70 always mean scleroderma?
Not necessarily. Scleroderma & Raynaud's UK explains that no single test gives a yes or no answer. Systemic sclerosis is diagnosed by looking at the whole person: symptoms, a physical examination and blood tests, usually by a rheumatologist.
Pathology Tests Explained notes that if someone has symptoms that fit a specific autoimmune condition and the matching antibody is positive, the condition becomes more likely. If there are no matching symptoms, the result is harder to interpret. Some people with a positive result may be in a very early stage, before skin changes appear.
Lab methods also differ. A 2025 review in Frontiers in Immunology notes that multiplex line-blot assays can vary by antigen and suggests confirming borderline Scl-70 results with a different method. It is worth asking which test was used and whether the result was strongly or weakly positive.
Why does Scl-70 matter for the lungs?
Scl-70 is strongly associated with interstitial lung disease (ILD), a type of lung scarring. Reviews describe earlier onset, greater extent and faster decline in breathing test results in the first years of disease among people with this antibody. Lung disease is a major driver of long-term outcomes in this group, which is why it is looked for early.
In 2023 the American College of Rheumatology published guidance for people with systemic autoimmune rheumatic diseases, including systemic sclerosis, who are at increased risk of ILD. It conditionally recommends screening with pulmonary function tests (PFTs) and a high-resolution CT (HRCT) scan of the chest, and recommends against screening with a plain chest X-ray alone.
PFTs measure how much air the lungs hold and how well oxygen passes into the blood, a measure often reported as DLCO or gas transfer. HRCT gives detailed pictures that can show early scarring before it causes symptoms. It is worth asking whether these tests should be repeated in your case, and how often, even if the first results are normal.
If ILD is found, the same guidance suggests repeat breathing tests every 3 to 6 months in the first year for systemic sclerosis, then less often once stable. Your team will decide what fits your situation.
What is the link between Scl-70 and Raynaud's?
Raynaud's phenomenon is when fingers or toes change colour, often white, blue or red, in the cold or with stress. It is common and usually harmless on its own. In systemic sclerosis it is often one of the first signs: Raynaud's is very common in scleroderma and can come before other signs.
In people with Scl-70, Raynaud's often lasts a shorter time before skin thickening starts, and fingertip ulcers are more common. That is why new Raynaud's in an adult with a positive Scl-70 usually leads to closer review rather than a wait-and-see approach.
What happens at a rheumatology referral?
A positive Scl-70 with symptoms usually leads to referral to a rheumatologist. Scleroderma & Raynaud's UK describes early diagnosis as a window of opportunity: finding the condition early can allow treatment to start sooner and complications in the lungs, heart, kidneys or gut to be picked up faster.
The same 2025 review notes that people with Scl-70 can also have heart, gut and, less often, kidney involvement, so checks are not limited to the lungs. Tests that may be arranged include:
- Nailfold capillaroscopy, which looks at tiny blood vessels at the base of the nails.
- Pulmonary function tests and a high-resolution chest CT.
- Heart tests, such as an ECG or an echocardiogram.
- Regular blood pressure checks and kidney function tests.
- Other antibody tests, including the rest of the ENA panel.
Questions to ask your clinician
These questions can help you understand your result and plan:
- Which test method was used, and was my Scl-70 strongly or weakly positive?
- Do my symptoms or examination findings fit systemic sclerosis?
- Should I have breathing tests and a high-resolution chest CT, and when?
- Do I need a rheumatology referral, and how soon?
- Which symptoms should make me contact the team before my next appointment?
- How often will my lungs, heart, blood pressure and kidneys be checked?
How comparing similar cases can help you prepare
On SameCase, patients and verified doctors share de-identified cases. Reading how others with a positive Scl-70 were assessed, which lung and heart tests they had, and what questions their doctors raised, can help you prepare a clearer list for your own appointment.
Other cases cannot tell you whether you have systemic sclerosis or how it will behave. Use them to prepare, and let your own care team interpret your results.
Sources and further reading
- Pathology Tests Explained (AACB): Extractable nuclear antigen antibodies, including Scl-70 (updated June 2023)
- Frontiers in Immunology (2025, CC BY): Clinical utility of autoantibodies in systemic sclerosis
- American College of Rheumatology: 2023 ILD screening and monitoring guideline summary
- Scleroderma & Raynaud's UK: Systemic sclerosis diagnosis tests and early diagnosis
- NHS: Scleroderma (reviewed March 2023)
- NHS: Raynaud's, when to see a GP (reviewed July 2023)
- NHS: Shortness of breath, when to call 999 (reviewed January 2024)
For patients & caregivers
Share your case and learn from others
Learn from doctors and other people's cases to find a way forward with your health problem. New cases are public immediately. Don't add names or identifying details.